Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionMetLife Investment Management, LLC
Latest Disclosed Ownership45,979 shares
Latest Disclosed Value $ 1,366,036
MetLife Investment Management, LLC reports 1.08% increase in ownership of TVTX / Travere Therapeutics, Inc.

On May 14, 2026 - MetLife Investment Management, LLC filed a 13F-HR form disclosing ownership of 45,979 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $1,366,036 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 45,487 shares of Travere Therapeutics, Inc.. This represents a change in shares of 1.08% during the quarter. The current value of the position is $2,078,251 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 45,979 492 1.08 1,366 -21.40 0.0070
2026-02-12 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 45,487 -7,091 -13.49 1,738 38.38 0.0084
2025-11-13 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 52,578 0 0.00 1,257 61.44 0.0060
2025-08-13 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 52,578 3,290 6.68 778 -11.89 0.0046
2025-05-14 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 49,288 4,577 10.24 883 13.50 0.0048
2025-02-13 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 44,711 3,568 8.67 779 35.30 0.0042
2024-11-13 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 41,143 311 0.76 576 71.64 0.0033
2024-08-13 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 40,832 7,843 23.77 336 31.89 0.0020
2024-05-14 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 32,989 -5,449 -14.18 254 -26.38 0.0017
2024-04-22 2023-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 38,438 0 0.00 346 0.58 0.0025
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 38,438 0 346 0.0025
2024-05-09 2023-09-30 13F/A-3 TRAVERE THERAPEUTICS COM 89422G107 38,438 0 0.00 344 -41.86 0.0027
2024-04-29 2023-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 38,438 0 344 0.0027
2023-11-14 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 38,438 0 344 0.0027
2024-04-29 2023-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 38,438 5,931 18.25 590 -19.29 0.0044
2023-08-10 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 38,438 5,931 590 0.0044
2024-05-09 2023-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 32,507 0 0.00 731 7.03 0.0054
2023-05-15 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 32,507 0 731 0.0054
2024-05-10 2022-12-31 13F/A-4 TRAVERE THERAPEUTICS COM 89422G107 32,507 0 0.00 684 -14.62 0.0053
2023-06-14 2022-12-31 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 32,507 0 684 0.0054
2023-03-23 2022-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 32,507 0 684 0.0055
2023-02-15 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 32,507 0 684 0.0054
2024-05-10 2022-09-30 13F/A-4 TRAVERE THERAPEUTICS COM 89422G107 32,507 0 0.00 801 1.65 0.0069
2023-06-14 2022-09-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 32,507 0 801 0.0070
2023-03-23 2022-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 32,507 0 801 0.0071
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 32,507 0 801 0.0032
2024-05-10 2022-06-30 13F/A-4 TRAVERE THERAPEUTICS COM 89422G107 32,507 -1,292 -3.82 788 -9.64 0.0063
2023-06-20 2022-06-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 32,507 -1,292 788 0.0064
2023-03-23 2022-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 32,507 -1,292 788 0.0065
2022-08-11 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 32,507 -1,292 788 0.0026
2024-05-10 2022-03-31 13F/A-4 TRAVERE THERAPEUTICS COM 89422G107 33,799 12,475 58.50 871 31.77 0.0058
2023-06-20 2022-03-31 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 33,799 12,475 871 0.0059
2023-03-23 2022-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 33,799 12,475 871 0.0059
2022-05-12 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 33,799 12,475 871 0.0036
2024-05-17 2021-12-31 13F/A-4 TRAVERE THERAPEUTICS COM 89422G107 21,324 0 0.00 662 27.85 0.0056
2023-06-21 2021-12-31 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 21,324 0 662 0.0057
2023-03-23 2021-12-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 21,324 0 662 0.0058
2022-02-15 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 21,324 0 662 0.0031
2024-05-17 2021-09-30 13F/A-4 TRAVERE THERAPEUTICS COM 89422G107 21,324 0 0.00 517 66.24 0.0048
2023-06-21 2021-09-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 21,324 0 517 0.0049
2023-03-23 2021-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 21,324 0 517 0.0048
2021-11-15 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 21,324 0 517 0.0025
2024-05-17 2021-06-30 13F/A-4 TRAVERE THERAPEUTICS COM 89422G107 21,324 0 0.00 311 -41.54 0.0028
2023-06-21 2021-06-30 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 21,324 0 311 0.0030
2023-03-23 2021-06-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 21,324 0 311 0.0029
2021-08-16 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 21,324 0 311 0.0015
2024-05-17 2021-03-31 13F/A-4 TRAVERE THERAPEUTICS COM 89422G107 21,324 21,324 532 0.0050
2023-06-26 2021-03-31 13F/A-2 TRAVERE THERAPEUTICS COM 89422G107 21,324 21,324 532 0.0052
2023-03-23 2021-03-31 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 21,324 21,324 532 0.0050
2021-05-14 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 21,324 21,324 532 0.0027
2024-05-24 2020-12-31 13F/A-4 RETROPHIN COM 761299106 0 0
2024-05-24 2020-12-31 13F/A-5 RETROPHIN COM 761299106 0 -21,324 -100.00 0 -100.00
2023-06-22 2020-12-31 13F/A-3 RETROPHIN COM 761299106 0 -21,324 0
2023-06-22 2020-12-31 13F/A-2 RETROPHIN COM 761299106 0 0
2023-03-22 2020-12-31 13F/A-1 RETROPHIN COM 761299106 0 -21,324 0
2021-02-16 2020-12-31 13F RETROPHIN COM 761299106 0 -21,324 0 0.0000
2024-05-24 2020-09-30 13F/A-4 RETROPHIN COM 761299106 21,324 2,482 13.17 394 2.34 0.0043
2023-06-26 2020-09-30 13F/A-2 RETROPHIN COM 761299106 21,324 2,482 394 0.0044
2023-03-23 2020-09-30 13F/A-1 RETROPHIN COM 761299106 21,324 2,482 394 0.0044
2020-11-13 2020-09-30 13F RETROPHIN COM 761299106 21,324 2,482 0 0.0024
2024-05-24 2020-06-30 13F/A-4 RETROPHIN COM 761299106 18,842 0 0.00 385 40.15 0.0044
2023-06-26 2020-06-30 13F/A-2 RETROPHIN COM 761299106 18,842 0 385 0.0045
2023-03-23 2020-06-30 13F/A-1 RETROPHIN COM 761299106 18,842 0 385 0.0045
2020-08-14 2020-06-30 13F RETROPHIN COM 761299106 18,842 0 0 0.0023
2023-07-12 2020-03-31 13F/A-2 RETROPHIN COM 761299106 18,842 0 0.00 275 2.62 0.0039
2023-03-23 2020-03-31 13F/A-1 RETROPHIN COM 761299106 18,842 0 275 0.0039
2020-05-15 2020-03-31 13F RETROPHIN COM 761299106 18,842 0 0 0.0019
2023-07-12 2019-12-31 13F/A-2 RETROPHIN COM 761299106 18,842 0 0.00 268 22.48 0.0029
2023-03-23 2019-12-31 13F/A-1 RETROPHIN COM 761299106 18,842 0 268 0.0029
2020-02-14 2019-12-31 13F RETROPHIN COM 761299106 18,842 0 0 0.0016
2023-07-12 2019-09-30 13F/A-2 RETROPHIN COM 761299106 18,842 0 0.00 218 -42.33 0.0025
2023-03-23 2019-09-30 13F/A-1 RETROPHIN COM 761299106 18,842 0 218 0.0024
2019-11-14 2019-09-30 13F RETROPHIN COM 761299106 18,842 0 0 0.0014
2023-07-12 2019-06-30 13F/A-2 RETROPHIN COM 761299106 18,842 0 0.00 379 -11.27 0.0042
2023-03-23 2019-06-30 13F/A-1 RETROPHIN COM 761299106 18,842 0 379 0.0041
2019-08-14 2019-06-30 13F RETROPHIN COM 761299106 18,842 0 0 0.0025
2023-07-13 2019-03-31 13F/A-3 RETROPHIN COM 761299106 18,842 0 0.00 426 0.00 0.0048
2023-03-23 2019-03-31 13F/A-2 RETROPHIN COM 761299106 18,842 0 426 0.0047
2019-05-17 2019-03-31 13F/A-1 RETROPHIN COM 761299106 18,842 0 0 0.0028
2019-05-15 2019-03-31 13F RETROPHIN COM 761299106 18,842 0 0
2023-07-13 2018-12-31 13F/A-2 RETROPHIN COM 761299106 18,842 0 0.00 426 -21.26 0.0053
2023-03-23 2018-12-31 13F/A-1 RETROPHIN COM 761299106 18,842 -10,491 426 0.0052
2019-02-14 2018-12-31 13F RETROPHIN COM 761299106 18,842 -10,491 0 0.0031
2023-07-13 2018-09-30 13F/A-2 RETROPHIN COM 761299106 18,842 0 0.00 541 0.0057
2023-03-23 2018-09-30 13F/A-1 RETROPHIN COM 761299106 29,333 10,491 843 0.0082
2018-11-14 2018-09-30 13F RETROPHIN COM 761299106 29,333 10,491 1 0.0051
2018-08-15 2018-06-30 13F RETROPHIN COM 761299106 18,842 2,439 14.87 1 -100.00 0.0061
2018-05-15 2018-03-31 13F RETROPHIN COM 761299106 16,403 0 0.00 0 -100.00 0.0043
2018-02-15 2017-12-31 13F RETROPHIN COM 761299106 16,403 16,403 0 0.0039
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.